Barclays analyst Andrew Mok raised the firm’s price target on Oscar Health (OSCR) to $13 from $11 and keeps an Underweight rating on the shares following the Q3 report. The company is putting though a weighted-average rate increase of 28%, with more competitive products in bronze and gold tiers, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR: